Nanogen Sends Expression System for Beta Testing; Announces Exec s Departure | GenomeWeb

NEW YORK, March 15 – Nanogen said Thursday it had shipped a new system designed for targeted gene expression applications for beta testing at two undisclosed US institutions and one in Europe.

Nanogen plans to use the results of the tests to develop new applications for detecting gene expression. Currently the company’s NanoChip system is primarily used do detect and analyze SNPs, short tandem repeats, and mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.